The Framingham Heart Study

弗雷明翰心脏研究是一项纵向队列研究，始于1948年，一直持续到今天。弗雷明翰心脏研究的目标是通过利用大量关于遗传学、行为、生物标记物、成像技术和环境因素的新的和现有的信息，显著扩展关于基因和环境对心肺、血液和睡眠(HLBS)疾病和紊乱的发展和进展的复杂影响的知识。这一目标是通过重新检查三个弗雷明翰队列(原始、后代、第三代)中的每一个来实现的；通过快速分发DNA以进行广泛和集中的基因分型；快速分发供弗雷明翰研究内部和外部研究人员使用的遗传和表型测量；以及通过分析基因、新的和已建立的风险因素以及创新的生物标记物对亚临床和临床疾病的发展和进展的贡献。 从2009年底开始，Framingham Omni队列将被整合到Framingham心脏研究的合同中。OMNI队列参与者由马萨诸塞州弗雷明翰的少数民族居民组成，由弗雷明翰心脏研究调查人员在1994-1995年(OMNI队列1)和2003-2005年(OMNI队列2)招募，以补充研究并反映该社区日益多样化的情况。OMNI的人群由西班牙裔、非裔美国人、亚洲人和一些美国印第安人组成。三次检查和一次检查分别在OMNI队列1和OMNI队列2上进行，资金来自NIH向波士顿大学提供的赠款。通过将OMNI队列整合到弗雷明翰心脏研究合同中，OMNI队列将始终接受与其余弗雷明翰心脏研究参与者相同的监测和检查。OMNI队列的整合将使研究结果更适用于社区。

The Framingham Heart Study is a longitudinal cohort study that began in 1948 and continues to this day. The objectives for the Framingham Heart Study are to significantly expand knowledge about the complex influences of genes and environment on development and progression of heart, lung, blood and sleep (HLBS) diseases and disorders, by utilizing the extensive array of new and existing information on genetics, behaviors, biomarkers, imaging techniques, and environmental factors. This objective is accomplished through re-examination of each of the three Framingham cohorts (Original, Offspring, Generation III) for measurement of complex phenotypes; through rapid distribution of DNA for extensive and focused genotyping; for rapid distribution of genetic and phenotypic measurements for use by investigators internal and external to the Framingham Study; and through analyses of the contribution of genes, new and established risk factors, and innovative biomarkers to the development and progression of subclinical and clinical disease. Starting in late 2009, the Framingham Omni cohorts will be integrated into the contract for the Framingham Heart Study. The Omni cohort participants, consisting of minority residents of Framingham, MA, were recruited by Framingham Heart Study investigators in 1994-1995 (Omni Cohort 1) and 2003-2005 (Omni Cohort 2) to complement the study and reflect the growing diversity of that community. The Omni cohorts consisted of Hispanics, African Americans, Asians, and a few American Indians. Three examinations and one examination were conducted on the Omni Cohort 1 and Omni Cohort 2, respectively, with funding provided through NIH grants to Boston University. By integrating the Omni cohort into the Framingham Heart Study contract, the Omni cohorts will consistently receive the same surveillance and examination as the rest of the Framingham Heart Study participants. The integration of the Omni cohort will make the study findings more applicable to the community.